Immunotherapy combo may outperform chemo in rare lymphoma
NCT ID NCT07678229
First seen Jul 01, 2026 · Last updated Aug 14, 2026 · Updated 5 times
Summary
This Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assigned to one of two treatment paths. The study aims to see which approach leads to better event-free survival at two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, pegaspargase, anlotinib, gemcitabine, etoposide, methotrexate, dexamethasone
- What this could lead to
- If successful, this could establish a more effective, less toxic frontline immunotherapy-based regimen for advanced NK/T-cell lymphoma, potentially improving long-term survival.
- What could go wrong
- This is a Phase 3 trial, but the experimental arm combines multiple drugs, which may increase side effects. The study is relatively small (150 participants), and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center,
RECRUITINGShanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Engineered donor cells take aim at tough blood cancers in early trial
- Promising combo may slash radiation harm in rare lymphoma
- New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
- New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients
- New pill shows early promise against tough cancers